Rachael Brake on Mobocertinib (TAK-788) for the Treatment of NSCLC #AACR2020 @rachael_brake @TakedaOncology

Rachael Brake on Mobocertinib (TAK-788) for the Treatment of NSCLC #AACR2020 @rachael_brake @TakedaOncology

Cancer-News

3 weeks
16 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations

__________

The Breakthrough Therapy Designation is based on the overall response rate (ORR) and the long-term benefit seen in patients who responded in a Phase 1/2 study evaluating the safety and efficacy of mobocertinib in patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations and have been previously treated with systemic chemotherapy. This signals a potential advancement in addressing the needs of patients for whom no targeted therapies exist and current treatment options provide limited benefit.

Read here: https://www.businesswire.com/news/home/20200427005219/en/Takeda-Announces-U.S.-FDA-Breakthrough-Therapy-Designation

Up Next Autoplay